Protection from Endogenous Perforin: Glycans and the C Terminus Regulate Exocytic Trafficking in Cytotoxic Lymphocytes  by Brennan, Amelia J. et al.
Immunity
ArticleProtection from Endogenous Perforin: Glycans
and the C Terminus Regulate Exocytic Trafficking
in Cytotoxic Lymphocytes
Amelia J. Brennan,1,2 Jenny Chia,1 Kylie A. Browne,1 Annette Ciccone,1 Sarah Ellis,1 Jamie A. Lopez,1,2 Olivia Susanto,1
Sandra Verschoor,1 Hideo Yagita,5 James C. Whisstock,6,7 Joseph A. Trapani,1,3 and Ilia Voskoboinik1,2,4,*
1Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3002, Australia
2Department of Pathology
3Microbiology and Immunology
4Department of Genetics
The University of Melbourne, Victoria 3052, Australia
5Department of Immunology, Juntendo University School of Medicine, Tokyo, 113-8421, Japan
6Department of Biochemistry and Molecular Biology
7The ARC Centre of Excellence in Structural and Functional Microbial Genomics
Monash University, Clayton, Victoria 3800, Australia
*Correspondence: ilia.voskoboinik@petermac.org
DOI 10.1016/j.immuni.2011.04.007SUMMARY
Cytotoxic lymphocyte-mediated apoptosis is depen-
dent on the delivery of perforin to secretory granules
and its ability to form calcium-dependent pores in the
target cell after granule exocytosis. It is unclear how
cytotoxic lymphocytes synthesize and store perforin
without incurring damage or death. We discovered
that the extreme C terminus of perforin was essential
for rapid trafficking from the endoplasmic reticulum
to the Golgi compartment. Substitution of the
C-terminal tryptophan residue resulted in retention
of perforin in the ER followed by calcium-dependent
toxic activity that eliminated host cells. We also
found that N-linked glycosylation of perforin was crit-
ical for transport from the Golgi to secretory gran-
ules. Overall, an intact C terminus and N-linked
glycosylation provide accurate and efficient export
of perforin from the endoplasmic reticulum to the
secretory granules and are critical for cytotoxic
lymphocyte survival.INTRODUCTION
Perforin (PRF; PRF1) is a cytotoxic pore-forming glycoprotein
that is crucial for cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells, collectively known as cytotoxic lymphocytes
(CLs), to kill virus-infected and transformed cells (Dennert and
Podack, 1983; Henkart et al., 1986; Law et al., 2010; Podack
and Dennert, 1983; Podack et al., 1985; Thiery et al., 2010).
PRF deficiency in both mice and humans results in severe immu-
nodeficiency. Genetically engineered PRF-deficient mice are
abnormally susceptible to many viruses (Ka¨gi et al., 1994), and
about 60%spontaneously develop aggressive B cell lymphomas
as they age (Smyth et al., 2000; Street et al., 2002). Humaninfants born without functional PRF develop an aggressive
immunoregulatory disorder, familial hemophagocytic lympho-
histiocytosis (FHL), typically during the first few months of life
(Katano and Cohen, 2005; Stepp et al., 1999). This condition is
generally fatal unless treated with cytotoxic drugs and/or bone
marrow transplantation (Henter et al., 2007). Partial PRF defi-
ciency is associated with atypical late-onset FHL and various
hematological malignancies (Brennan et al., 2010; Chia et al.,
2009).
PRF is stored in lysosome-like secretory granules of CLs,
together with proapoptotic serine protease granzymes (Barry
and Bleackley, 2002; Sutton et al., 2003). Upon formation of
a transient conjugate between a CL and a target cell, secretory
granules are mobilized toward the synapse and fuse with the
plasma membrane to release PRF and granzymes. The neutral
pH and high extracellular Ca2+ of the immune synapse induce
PRF binding to phospholipid membranes and polymerization
into a transmembrane pore, which subsequently allows gran-
zymes to access the cytosol and cleave cytosolic substrates to
initiate various apoptotic death mechanisms in the target cell
(Bolitho et al., 2007; Trapani and Smyth, 2002). So how do cyto-
toxic lymphocytes manage this toxic cargo?
Granzymes are trafficked to secretory lysosomes as zymo-
gens predominantly via the mannose-6-phosphate receptor
(MPR) pathway (Griffiths and Isaaz, 1993) and subsequently pro-
cessed by dipeptidyl peptidase I (Cathepsin C) to an active form
(Pham and Ley, 1999; Smyth et al., 1995) and also by Cathepsin
H in the case of granzyme B (GzmB) (D’Angelo et al., 2010).
Should granzymes ‘‘leak’’ into the cytosol of the CL, serpins
such as PI-9 or SPI-6 efficiently and irreversibly inactivate
them (Bird et al., 1998; Hirst et al., 2003). Whereas the synthesis
and activation of granzymes is well characterized, how CLs
manage the lethal burden of PRF, particularly during cell activa-
tion when large quantities of the highly toxic protein are
produced, remains a critical question of CL biology.
Although PRF is inactive in acidic secretory granules (Uellner
et al., 1997; Voskoboinik et al., 2005), it is unclear howCLs evade
PRF toxicity or polymerization in the endoplasmic reticulum (ER),Immunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc. 879
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Figure 1. Cytotoxicity of Recombinant WT
and Mutant PRF
(A) Schematic representation of PRF molecules
expressed in this study. Diamond indicates
glycosylation site; 3 indicates mutation of glyco-
sylation site. See Table 1 for detailed annotation.
(B and C) Lysis of sheep red blood cells (SRBC) by
purified recombinant mouse Del-12 and Gly1+
Gly2 PRF; data shown are mean ± SE (n = 3).
Immunoblot shows serial dilutions of the purified
PRF.
(D) Jurkat T cell apoptosis was induced by sublytic
concentrations of purified recombinant mouseWT
and Gly1+Gly2 PRF with various concentrations of
human GzmB, as measured by annexin V and
7AAD double staining after a 2 hr exposure.
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Mechanisms of Perforin Traffickingwhich has conditions favorable for PRF pore formation—neutral
pH and high calcium. It is also unknown what governs safe
targeted delivery of PRF from the ER to the secretory granules.
In the past, it has been hypothesized that the potential mecha-
nism of PRF regulation might involve steric inhibition of calcium
binding to the PRF C2 domain (Uellner et al., 1997). However,
a recently resolved crystal structure of PRF reveals spatial
constraints that are predicted to preclude the C-terminal 12
amino acid glycopeptide of PRF acting in this way. The crystal
structure shows that the C-terminal ‘‘tail’’ appears to be diverted
away from the calcium binding moieties of the C2 domain (Law
et al., 2010).
The current study addresses the complex issue of PRF
toxicity, trafficking, and effector cell resistance. We discovered
that CLs are protected from PRF toxicity by virtue of efficient880 Immunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc.and rapid export from the ER. The last, in-
variantly conserved residue of PRF
(W555) regulated this process, and any
appreciable delay in export from the ER
resulted in death of the host cell. Finally,
we demonstrated that PRF delivery to
the secretory granules is regulated by its
N-linked glycans (potentially through the
MPR pathway); however, an additional
and less efficient glycan-independent
pathway also provided constitutive traf-
ficking of PRF.
RESULTS
The C Terminus and Attached
Glycan Are Dispensable for PRF
Function In Vitro
To investigate how the potentially toxic
activity of newly synthesized PRF can
be managed by the host cell, we consid-
ered the role of the last 12 C-terminal
amino acids to design various recombi-
nant PRF expression vectors. It is sus-
pected that the extreme C-terminal
peptide must be removed for PRF to
become active, so we used baculovirus-infected insect cells to express a ‘‘zymogenic’’ full-length form
of the protein (z-PRF) that would be nontoxic but capable of
being activated by proteolytic cleavage after purification (see
Figure S1A available online). To accommodate this strategy,
we engineered a protease cleavage site 12 amino acids from
the carboxy terminus (Figure S1A). Surprisingly, the uncleaved
purified z-PRF was as efficient in inducing calcium- and
GzmB-dependent target cell death as purified wild-type (WT)
PRF (Figure S1B), and cleavage of the zymogenic form did not
further enhance PRF activity (data not shown). In support of
this finding, the activity of a PRF mutant that had the 12
C-terminal residues deleted (Del-12 PRF; Figures 1A and 1B;
Figure S1B) also had WT activity.
We considered the possibility that z-PRF or WT PRF might
have been processed nonspecifically by an unknown protease(s)
Immunity
Mechanisms of Perforin Traffickingexpressed in insect Sf9 cells. However, when both forms of PRF
were digested to completion with trypsin and the resulting
peptide fragments analyzed on a mass spectrometer, the
extremeC-terminal pentapeptide together with the hexahistidine
tag was readily detectable, indicating that the C terminus of
z-PRF and of WT PRF were indeed intact (data not shown).
Because the removal of the C-terminal glycan (referred to as
Gly2 in this study) was also proposed to be important for PRF
function (Uellner et al., 1997), we generated a deglycosylated
form of PRF (Gly1+Gly2), which was also found to be fully func-
tional (Figures 1C and 1D). Finally, peptide-N4-(acetyl-b-gluco-
saminyl)-asparagine amidase F (PNGaseF) treatment that
completely deglycosylated WT PRF also had no effect on the
lytic activity of the protein or its ability to synergize with GzmB
(Law et al., 2010; data not shown).
These results confirmed that neither extremeC-terminal modi-
fications nor deglycosylation were required for PRF’s intrinsic
lytic activity (and, hence, membrane binding). These findings
were also consistent with the recently published crystal structure
of full-length perforin (Law et al., 2010), which has the extreme C
terminus situated more than 70 A˚ away from the C2 domain (see
Discussion). We therefore considered the alternative possibility
that either the extremeC-terminal peptide or the attached glycan
might be important for accurate PRF processing or trafficking in
a cellular environment.
Expression of C-Terminal Mutants of PRF Result
in the Autolysis of Host Cells
We examined the expression of PRF in RBL cells transiently
transfected with the PRF mutants Gly2 and Del-12. RBL cells
were sorted 20–24 hr posttransfection on the basis of identical
mean green fluorescence protein (GFP) fluorescence, as driven
off the mammalian expression vector pIRES2-EGFP into which
the PRF cDNA was cloned (Voskoboinik et al., 2004).
A close examination of fluorescence profiles revealed that
although Gly2 PRF-transfected RBL cells were able to tolerate
lowGFP expression, the proportion of highGFP-expressing cells
was significantly reduced in comparison toWTPRF, with a corre-
sponding increase in propidium iodide (PI)-stained cells (Fig-
ure 2A; Figure S2A). Whereas the median (50%) cells expressing
WT PRF had more than 6.3 times the background fluorescence
of untransfected cells, the median cells expressing Gly2 PRF ex-
pressed at only 3.7 times the background fluorescence. Similar
observations were also made for the Del-12 mutant (Figure 2A).
The differences were even more dramatic for the top 10% and
25% GFP-expressing cells (Figure 2A). These results suggested
that a reduction in the expression of Gly2 and Del-12 PRF might
be due to intracellular cytotoxicity, because the corresponding
purified Del-12 PRF expressed in baculovirus-infected cells
had WT lytic activity (Figure 1B; Figure S1B).
Previously, we identified five key aspartate residues in the C2
domain of PRF, which were all critical for calcium-dependent
membrane binding to the target cell membrane (Voskoboinik
et al., 2005). The substitution of any of these aspartates (e.g.,
D484A; DA in this paper) resulted in the loss of cytolytic activity
without any measurable effect on the stability (Figures S2B and
S2C) or granule localization of the mutant PRF (Voskoboinik
et al., 2005). To test whether the loss of RBL cells that are high
expressors of Gly2 and Del-12 PRF was indeed due to intracel-lular toxicity, we introduced the DA-inactivating mutation in the
C2 domain to produce double mutants Gly-2 DA PRF and
Del-12 DA PRF. We found that the GFP profiles of the mutants
were now similar to those of WT PRF (Figure 2A), and consistent
with this, the cell death was proportionally reduced, indicating
that high-expressing cells were rescued (Figure S2A). This was
not due to protein degradation, because the amounts of Gly2
and Del-12 were essentially identical to those of Gly2 DA and
Del-12 DA, respectively, in the sorted populations (Figure S2C).
As predicted, the transfected cells showed no cytotoxic activity
(data not shown). It is important to note that Del-12 PRF is
missing the Gly2 site, explaining the loss of the high-molec-
ular-weight bands.
To further verify the intracellular toxicity of Del-12, RBL cells
were transfected with Del-12 and the Del-12 DA double mutant
and the expression of GFP was followed in real time by time-
lapse microscopy. Del-12-transfected cells tolerated only low
amounts of GFP expression and many of these cells were noted
to undergo rapid cytolysis soon after acquiring GFP fluores-
cence (Figure 2B; Movie S1). Introduction of the DA mutation
reversed the toxic phenotype of Del-12 so that transfected cells
tolerated significantly higher GFP expression and retained
viability (Figure 2B; Movie S2).
We next transfected the C-terminal mutants into activated
primary CTLs isolated from Prf1/ mice that were also trans-
genic for the OT-I T cell receptor. Significant cell death of the
high GFP-expressing population was again noted (Figure S2D);
however, enough cells were recovered to perform cytotoxicity
assays. The activity of Gly2 mutant-expressing CTLs was iden-
tical to that of WT PRF-transfected cells, whereas the Del-12
PRF mutant had less than 50% activity (Figure 2C).
To test the behavior of these PRF mutants in the context of
human CLs, we generated PRF-silenced clones of the human
NK cell line KHYG1 (Figure S2E). The silenced clones were
then virally transduced with WT or mutant PRF cloned into the
MSCV-IRES-GFP vector. Stable clones were selected on the
basis of identical GFP fluorescence. Similar to RBL cells and
CTLs, GFP profiles in PRF-silenced KHYG1 human NK cells
revealed a reduction in the proportion of high GFP (and thus
Gly2 and Del-12 PRF)-expressing cells in comparison to when
the inactivating DA mutations were additionally introduced (Fig-
ure S2F). Cytotoxic assays based on equivalent PRF expression
also showed that the Gly2 mutant was completely active,
whereas the Del-12 mutant had reduced activity in comparison
with WT PRF (Figure 2D). Importantly, the amounts of intracel-
lular recombinant PRF in all cell types tested were similar to or
less than those detected in primary human NK cells (Figure S2G;
Voskoboinik et al., 2004), supporting the physiological relevance
of our observations.
Overall, the analyses of purified recombinant PRF demon-
strates that modifications of the PRF extreme C terminus do
not influence intrinsic protein stability and cytolytic activity.
Rather, these modifications markedly affect the viability of host
effector cells.
The Final C-Terminal Residue Is Essential for Protecting
CLs from PRF Toxicity
The extreme C-terminal dodecapeptide of PRF, GEPPGNRSG
AVW, is almost invariantly conserved in mammals. Furthermore,Immunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc. 881
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Figure 2. Host Cells Expressing C-Terminal Mutants Undergo Autolysis
(A) RBL cells were transiently transfected with WT PRF, Gly2, Gly2 DA, Del-12, Del-12 DA, WS, and WS DA PRF (histograms). Bar charts show the threshold of
GFP fluorescence that was tolerated by the top 50%, 25%, and 10%GFP-expressing cells (lower boundaries are defined on the schematic). This was estimated
as a fold increase over the highest autofluorescence boundary of untransfected RBL cells (GFP+ on the schematic). Table summarizes relative threshold values of
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Mechanisms of Perforin Traffickingeven though the C terminus is extremely divergent in lower verte-
brates such as fish, the final C-terminal residue (W555) is always
a bulky hydrophobic amino acid. To test the importance of this
residue, W555 was substituted with a small polar serine (WS).
Remarkably, WS was as toxic to effector cells as the Del-12
mutant (Figure 2A; Figures S2A, S2D, and S2F), and, similar to
Del-12, resulted in reduced activity when expressed in Prf1/
primary mouse CTLs (Figure 2C) and PRF-silenced KHYG1 cells
(Figure 2D). Once again, death of the transfected cells was
rescued by additionally incorporating the DA mutation (WS DA
PRF; Figure 2A; Figure S2F), indicating that cellular toxicity was
due to the function of an active PRF molecule.
To substantiate this further, we employed another strategy.
Previously, we identified the interacting residues between
successive PRF monomers within a transmembrane pore and
found that the mutation R213E severely disrupts PRF oligomer-
ization and, consequently, cytotoxic activity (Baran et al., 2009).
This mutant has no effect on PRF folding and membrane binding
(Baran et al., 2009). Engineering R213E into the toxic WSmutant
(WS R213E) rescued the high-GFP population, similar to the
effect of the C2 domain DA mutation, which further suggests
that toxicity is due to PRF pore formation (Figure S2H). Further-
more, the rescue by WS R213E was incomplete, consistent with
the fact that the R213E mutant maintains some residual activity
(Baran et al., 2009).
N-Linked Glycosylation at the C Terminus
Does Not Protect the Effector Cell from PRF Toxicity
Rescue of transfected cells expressing the C-terminal mutants of
PRF through inactivation of the C2 domain suggested that the
mutants exhibited their toxicity through a Ca2+-dependent
mechanism and were being inappropriately activated within
the effector cell. The only intracellular compartment that would
fulfill the minimum essential criteria for PRF activity (neutral pH
and high Ca2+) is the ER. It has been suggested previously that
glycosylation of PRF at the C terminus renders the protein inac-
tive, providing a protective mechanism for cells that store and
secrete PRF (Uellner et al., 1997). TheWSPRFmutant was highly
toxic to the host cell, so we hypothesized that the mutant might
not be glycosylated at the C terminus. However, endoglycosi-
dase H (EndoH) and PNGaseF treatment of cell lysates indicated
that WS PRF had WT glycosylation (Figure 2E; Figure S2C).GFP fluorescence for each PRF mutant represented in bar charts above. For cla
represented as mean ± SE (n = 7–15) and statistics were obtained with a one-w
*p < 0.01.
(B) Live cell microscopy stills of RBL cells transiently transfected with Del-12 and
DA PRF does not result in PI staining by 8.5 hr. Accumulation of GFP fluorescence
morphological changes (shrinking) of Del-12 but not Del-12 DA-expressing cells.
comparison to Del-12 DA PRF (n = 42 cells). Data are represented as mean ± SE a
Scale bar represents 30 mm.
(C) 51Cr release assay via PRF-transfected and sorted (according to identical m
pulsed EL-4 target cells at the effector/target (E/T) ratios indicated. The values plo
of 3 independent experiments for each mutant and of 11 independent experiment
WT PRF at 10:1 E/T ratio (100%); average maximal lysis was 46.3% ± 4.1%.
(D) 51Cr release assay via PRF-silenced KHYG1 cells (shPRF) stably transduced w
at the effector/target (E/T) ratios indicated. The values plotted represent relative
experiments for each mutant and of seven independent experiments for WT PRF a
10:1 E/T ratio (100%); average maximal lysis was 50.3% ± 6.2%.
(E) Immunoblot shows the relative PRF expression in each of the RBL cell popul
(F) Immunoblot shows the relative PRF expression in each of the RBL cell populBecause PRF has two glycosylation sites, we eliminated the
other site (N205) to formally demonstrate whether WS PRF still
maintained glycosylation near the C terminus. We interfered
with glycosylation by making an amino acid substitution at
S207, which forms part of the N-glycosylation consensus
sequence N(205)-X-S(207), resulting in S207D PRF (Gly1). The
Gly1 mutant retained full cytotoxic activity in RBL cells, indi-
cating that absence of this glycosylation was not important either
for PRF folding or lytic function (see below). The Gly1 mutant re-
mained glycosylated at the C terminus; immunoanalysis showed
reduced size consistent with the loss of one glycan moiety, and
PNGaseF treatment further reduced the protein size (see below).
Next, we engineered Gly1 on the WS PRF backbone (Gly1 WS
PRF). The resultant protein still maintained the C-terminal glyco-
sylation moiety as demonstrated by glycosidase treatment, thus
providing evidence that the WS mutation did not influence PRF
glycosylation at the C terminus (Figure 2F).
We therefore conclude that C-terminal glycosylation of PRF in
the ER is not sufficient to protect the cell from PRF toxicity. This
is consistent with the structural data, which show spatial
constraints that are likely to prevent a direct putative interaction
of the Gly2-attached mannose-rich glycan with the C2 domain
(Law et al., 2010). Therefore, our experimental evidence sup-
ported by the crystal structure of PRF shows that the C-terminal
glycosylation of PRF and the C terminus motif itself does not
inhibit PRF or protect the host cell.
The C Terminus of PRF Is Required for Exit from the ER
As alteration of the extreme C terminus did not affect the intrinsic
function of recombinant PRF, but markedly affected the viability
and cytotoxic function of transfected host cells, we hypothe-
sized that PRF export from the ER may be impaired. To address
this issue, we investigated the intracellular localization of Gly2,
Del-12, and WS mutants of PRF in RBL cells. WT PRF did not
colocalize with early endosome (EEA-1) or late endosome
(MPR) markers (Figure S3A). At steady state, the majority of
WT PRF colocalized with LAMP-1, indicating that PRF was
sorted into the lysosomal and/or granule compartment
(Figure S3B). The brightness of Gly2, Del-12, and WS PRF stain-
ing was low in comparison to WT PRF when we used compa-
rable confocal settings (Figure S3C). However, when the inten-
sity of the laser was increased to allow localization to berity, the same trace of WT PRF has been reproduced in each panel. Data are
ay ANOVA with Newman-Keuls Multiple Comparison Test post-hoc analysis;
Del-12 DA PRF. Accumulation of GFP fluorescence in a cell expressing Del-12
in a cell expressing Del-12 PRF results in PI staining at 7 hr. DIC images show
Del-12 PRF (n = 28 cells) has a significantly lower GFP fluorescence intensity in
nd statistics were obtained with a paired two sample for means t test; *p < 0.05.
ean GFP fluorescence) primary CTLs from Prf1/ OT-I mice, and SIINFEKL-
tted represent relative percent 51Cr release and the data shown are mean ± SE
s for WT PRF and the negative control. All values have been normalized against
ithWT, Gly2, Del-12,WSPRF, or the vector-alone control, and K562 target cells
percent 51Cr release and the data shown are mean ± SE of three independent
nd the vector-only control. All values have been normalized against WT PRF at
ations in the presence of EndoH (+) or buffer-only control (-).
ations in the presence of PNGaseF (+) or buffer-only control (-).
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Figure 3. Delayed ER Export of C-Terminal PRF Mutants
(A and B) Confocal microscopy of RBL cells transiently transfected withWT PRF, WSmutant PRF, Del-12 (Figure S3D), and Gly2 PRF (Figure S3E). The ER, TGN,
and PRFwere detected as per Experimental Procedures. After electroporation, the cells were incubated either at 37C (24 hr) or at 15C for 12 hr (time 0) to inhibit
protein traffic from the ER to the Golgi compartment and subsequently warmed to 37C for the times indicated. For clarity, ER and TGN colocalization of PRF in
the same cell were separated. Scale bars represent 10 mm.
(C) PRF colocalization with the ER and the TGN was analyzed with a correlation coefficient for confocal images as detected with Metamorph Analysis Software.
WT PRF colocalized with the ER for a shorter period of time than Gly2, Del-12, and WS PRF; *p < 0.05. Consistent with this, WT PRF migrated to the TGN faster
than the PRFmutants (*p < 0.05), andGly2 PRFmigrated to the TGN faster than Del-12 andWSPRF (yp < 0.05). Only GFP-expressing cells were assessed for PRF
expression. Results are mean ± SE (n = 5–14 cells) for each time point and statistics were obtained with a one-way ANOVA with Newman-Keuls Multiple
Comparison Test post-hoc analysis.
(D) Acquisition of EndoH resistance in the presence of EndoH (+) or buffer-only control (-) byWT PRF andWSmutant PRF after a 12 hr incubation at 15C (time 0),
with subsequent release of the trafficking blockade for the indicated periods of time at 37C. Both WT PRF andWS mutant PRF acquire some EndoH resistance
when cultured at 37C under steady-state conditions for 24 hr (see Figure 2E).
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Mechanisms of Perforin Traffickingassessed, all of the C-terminal mutants were also associated
with the granule compartment (Figure S3B). This was an unex-
pected observation, because these PRF mutants were toxic
but appeared to have undergone trafficking from the ER to the
granules.
To reconcile these findings, we considered the possibility that
mutant PRF could have a delayed rate of export from the ER. To
compare the rates of WT and mutant PRF trafficking, transiently
transfected RBL cells were incubated at 15C (for 12 hr),
a temperature at which trafficking from the ER to the Golgi
compartment is inhibited (Saraste and Kuismanen, 1984). The
temperature of cell culture was then increased to 37C for up
to 4 hr and protein export from the ER was followed. Immunoflu-
orescence analysis of cells at various time points after tempera-
ture shift to 37C revealed that whereas WT PRF was exported
from the ER within 30 min (Figures 3A and 3C), the WS and
Del-12 PRF were retained in the ER for at least 2 hr (Figures 3B
and 3C; Figure S3D). A similar result was also observed for WS
DA and Del-12 DA, indicating that Ca2+-dependent membrane
binding did not influence retention of the C-terminal mutants in
the ER (data not shown). In contrast, although Gly2 PRF
appeared to be exported to the trans-Golgi network (TGN) within
30 min, a significant amount of ER colocalization was still
observed for up to 2 hr (Figure 3C; Figure S3E).
Delayed export from the ER to the TGN was also expected to
manifest in slower acquisition of complex glycosylation, and
thus, greater sensitivity to EndoH treatment. To demonstrate
this, we conducted a pulse-chase experiment, where WT PRF
and WS, Del-12, and Gly1 mutant PRF-transfected cells were
cultured overnight at 15C, than warmed to 37C for various
periods of time in the presence of cyclohexamide, harvested,
and treatedwith EndoH glycosidase. Consistent with themicros-
copy data, although WT and Gly1 PRF acquired some EndoH
resistance within 30 min of being shifted to 37C, WS and Del-
12 PRF remained EndoH sensitive for at least 4 hr (Figure 3D;
Figure S3F). Similar results were observed with metabolic
35S-(Met+Cys) labeling and subsequent pulse-chase analysis
(Figure 3E).
We also analyzed the subcellular localization of another dele-
tion mutant, which was missing 19 C-terminal amino acids
(Del-19, which was also examined and named perf-515 by
Uellner et al. [1997]). In contrast to Del-12 or WS, Del-19 was
completely retained in the ER (Figure S3G; Uellner et al., 1997)
and did not display the same toxic phenotype as the other
C-terminal mutants (data not shown). This is consistent with
the prediction based on the crystal structure of PRF that such
an extensive deletion would interfere with PRF folding because
it extends into the ‘‘shelf’’ region (Law et al., 2010). Consistent
with ER retention, Del-19 had no cytotoxic activity when ex-
pressed in Prf1/ primary mouse CTLs (Figure S3G).
Overall, these results establish that the C-terminal tail of PRF,
specifically the last residue, regulates the rate of PRF export from
the ER, and this appears to be the critical step in preventing PRF(E) Acquisition of EndoH resistance in the presence of EndoH (+) or buffer-only co
and the subsequent pulse-chase in complete nonradioactivemedia for 0–4 hr. The
EndoH-sensitive DA or WS DA protein was normalized to the percentage of deg
sensitivity at 0–4 hr was calculated as ([deglycosylated PRF TX/total radioactive P
30, 120, and 240 min. PNGaseF-treated DA and WS DA PRF were used as positoxicity in the effector cell. Importantly, PRF toxicity could not be
ascribed simply to protein overexpression because (1) inactive
nontrafficking Del-12 DA or WS-DA had no toxic effect despite
being highly expressed (Figures S2C and S2F) and (2) PRF
expression in the recombinant system was similar to endoge-
nous PRF expression in human NK cells (Figure S2G). Finally,
these findings demonstrate that PRF toxicity can occur and
manifest at the earliest stages of posttranslational processing
in the ER.Delayed Trafficking of WT PRF from the ER Is Toxic
to the Host Cell
If the PRF variants tested above were truly causing toxicity
because of delayed export from the ER, then the retention of
unaltered WT PRF in the ER should also be toxic to the cell. To
test this, transiently transfected RBL cells were incubated at
15C to allow PRF to accumulate in the ER. The intracellular
transport of proteins from the ER to Golgi was disrupted with
brefeldin A (BFA) (a potent microtubule depolymerization agent,
which ‘‘dissipates’’ the TGN) (Klausner et al., 1992), prior to the
cells being incubated at 37C for 4 hr (Figure S4). We found
that incubation with BFA significantly reducedWT PRF-express-
ing cell survival, as evident from the reduced proportion of high
GFP-expressing cells (Figure 4). This finding mirrored the
behavior of nontrafficking C-terminal mutants WS and Del-12
(Figure 2A). In contrast, cells expressing PRF with the inactivat-
ing DA mutation had similar viability in the presence or absence
of BFA (Figure 4). These observations are consistent with the
24 hr experiments (see Figure 2A and Figure S2B), where the
proportion of high GFP-expressing cells was consistently higher
in DA mutant transfected cells compared to the WT PRF control.
We then engineered a canonical ER retention motif addition
(KDEL PRF) downstream of the C terminus of perforin. When
transiently transfected into RBL cells under steady-state condi-
tions, KDEL PRF also had a toxic phenotype, which could be
rescued through a second DA mutation (KDEL-DA PRF; data
not shown).
The toxic effect of WT PRF on the host cells with impaired ER
trafficking further confirms that retention of protein in the ER is
detrimental to the cell, but only when PRF is active. This excludes
the likelihood that cellular toxicity is due to nonspecific accumu-
lation of protein within the ER.Post-ER Processing of PRF
Because the C-terminal glycosylation of PRF in the ER was not
sufficient to protect cells from PRF toxicity, we explored whether
glycosylation moieties might be important for delivery of PRF to
the secretory lysosomes. Similar to many other glycoproteins,
acquisition of EndoH resistance of WT PRF indicated that it traf-
ficked through the Golgi compartment where it acquires
complex glycosylation (Figure 5A). Because mammalian PRF
contains two conserved glycosylation sites, we created a doublentrol (-) by DA and WS DA PRF at 37C with metabolic 35S-(Met+Cys) labeling
results were quantified and are presented as a graph, where the percentage of
lycosylated DA or WS DA at time 0 (T0; 100%), respectively. Relative EndoH
RF TX]/[deglycosylated PRF T0/total radioactive PRF T0]3 100%), where X = 0,
tive controls of completely deglycosylated PRF.
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Figure 4. Delayed Trafficking of WT PRF
from the ER Is Toxic to the Host Cell
The relative percentage of gatedWTPRF cells (M1)
incubated at 15C, with subsequent incubation at
37C for 4 hr in the presence of BFA, was signifi-
cantly lower than WT PRF cells incubated at 15C,
with subsequent incubation at 37C in the absence
of BFA (to allow trafficking from the ER); *p < 0.05.
In contrast, there was no significant difference
between treatments for DA PRF. Data are repre-
sented as mean ± SE (n = 3) and statistics were
obtainedwith apaired two-sample formeans t test.
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Mechanisms of Perforin Traffickingunglycosylated mutant (Gly1+Gly2), which was unable to kill
target cells when expressed in RBL cells (Figure 5A).
When tested in primary CTLs from Prf1/ mice, the Gly1 and
Gly2 glycosylation sitemutantswere fully active in comparison to
WT PRF, but the Gly1+Gly2 double mutation resulted in at least
80% loss of activity (Figure 5B). The transduction of Gly1+Gly2
into KHYG1 PRF-silenced cells revealed a similar loss of activity
in comparison with the fully active Gly2 mutant (Figure 5C). In
contrast, PNGaseF-treated purified recombinant WT PRF main-
tained full lytic function and ability to synergize with GzmB (Law
et al., 2010; data not shown). Taken together, these results
suggest that the loss of glycosylation does not affect the intrinsic
function of PRF but could potentially affect the delivery of PRF to
secretory granules.
The Interplay betweenGlycosylation and theC-Terminal
Peptide Regulates PRF Exocytic Trafficking
We went on to investigate the intracellular localization of Gly1,
Gly2, andGly1+Gly2mutants in RBL cells. Althoughwith compa-
rable confocal settings the intensity of PRF staining for the
Gly1+Gly2 mutant was low in comparison to WT PRF (Fig-
ure S5A), it was still found within the granule compartment and
colocalized with LAMP-1 under steady-state conditions
(Figure S5B).
We next investigated whether the lack of glycosylation
affected the rate of PRF export from the TGN to the lysosomes.886 Immunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc.Because Gly1+Gly2 PRF is not glycosy-
lated, we were unable to monitor exocy-
tosis with EndoH sensitivity as a marker
of trafficking through the TGN. As with
export from the ER, protein trafficking
from the Golgi to the secretory lysosomes
is temperature sensitive (Rodriguez-
Boulan et al., 1984; Saraste and Kuisma-
nen, 1992). Consistent with this observa-
tion, we found that WT PRF transiently
expressed in RBL cells cultured at 19C
for 12 hr was retained in the TGN (Fig-
ure 5D). Trafficking of WT PRF and single
glycosylation site mutants, Gly1 and
Gly2, from the TGNwas seen 30 min after
raising the temperature to 37C, with
more than 70% of WT PRF being trans-
ported from the TGN by 1.5 hr (Figures
5D and 5G; Figures S5C and S5D). In
contrast, Gly1+Gly2 PRF, which had bothglycosylation sites mutated, was largely retained in the TGN for
at least 1.5 hr after cells were moved to 37C (Figures 5E and
5G). Importantly, PRF retention at the TGN had no effect on
host cell survival, consistent with unobstructed ER-TGN traf-
ficking (data not shown). This indicates that glycosylation of at
least one site is needed for efficient trafficking of PRF from Golgi
to lysosomes.
To directly demonstrate a critical role of PRF glycosylation in
TGN-to-lysosome trafficking, we introduced an engineered
glycosylation site to the unglycosylated Gly1+Gly2 mutant. We
made an amino acid substitution, D376N, on the Gly1+Gly2
mutant background (Gain Gly PRF), which fulfilled the require-
ment for the N-linked glycosylation consensus motif, -NXS-.
Because some species have a glycosylated asparagine at this
position, we predicted that this mutation would not be detri-
mental to intrinsic PRF function. The Gain Gly PRF cDNA was
transfected into RBL cells to study PRF export from the TGN
by releasing the 19C temperature block and into PRF-deficient
primary CTLs for measuring cytotoxic activity. The results of
these assays showed that the Gain Gly PRF restored the rate
of export of Gly1+Gly2 from the TGN (Figures 5F and 5G) and,
most importantly, restored activity to that of WT PRF, when ex-
pressed in primary CTLs (Figure 6).
These results implicate a putative glycan-dependent pathway
(most probably MPR regulated) as the primary route for PRF
traffic from the TGN to the secretory granules. In the case of
Immunity
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pathway (data not shown), another less efficient transport mech-
anism is still capable of complementing some delivery of PRF to
the secretory granules and appears to be responsible for up to
20% of CTL or NK cell activity (see Gly1+Gly2 PRF in Figures
5B and 5C).DISCUSSION
The current study reveals how CLs maintain a balance between
the critical role of PRF in the secretory granule death pathway
and the neutralization of its extreme cytotoxicity during exocytic
trafficking.
Recent studies have revealed an evolutionary conservation of
membrane-attack-complex-PRF (MACPF) protein structures
(Law et al., 2010; Rosado et al., 2007, 2008). In addition to the
thermodynamically labile MACPF domain, the members of
this ubiquitous protein family also maintain a C-terminal
membrane-binding moiety, which in PRF is a Ca2+-binding C2
domain. The only unstructured region of PRF appears to be its
extreme C-terminal glycosylated dodecapeptide. This region
has been hypothesized to have an inhibitory function, possibly
by preventing calcium binding to the C2 domain and eliminating
the first step in PRF cytotoxicity—Ca2+-dependent membrane
binding (Uellner et al., 1997).
The current study has challenged this hypothesis, because we
have demonstrated that the removal of the C-terminal peptide is
not required for PRF activation. This is also predicted by the
crystal structure of PRF, which shows that the C-terminal glyco-
sylation site (on N549) and the C2 domain are separated by at
least 70 A˚ and are located on opposite sides of the molecule
(Law et al., 2010). N-linked glycosylation in the ER is highly
conserved and is generally limited to 14 branched hexose addi-
tions (Aebi et al., 2010; Helenius and Aebi, 2004), which would
stretch for approximately 30 A˚. Together, these data preclude
the C-terminal glycan from interacting with the Ca2+ binding
portion of the C2 domain in the ER. The structural data also
reveal that the C-terminal 12 amino acids are somewhat periph-
eral to the overall PRF structure making a modest number of van
der Waals contacts as well as a single hydrogen bond with the
rest of themolecule. These data are consistent with the observa-
tion that a PRF construct containing a 12 amino acid deletion
(544–555, which also contains the glycosylation site at N549) is
able to fold normally and maintain WT activity (Law et al., 2010).
Our observations reveal that rapid and efficient PRF transport
from the ER offered cell protection from the toxic cargo protein.
The same protective mechanism has been documented in the
past, most notably in the case of a-synuclein (Cooper et al.,
2006). It is important to emphasize that the previously held
view on the role of PRFs C terminus was based on the analysis
of a mutant with a substantial C-terminal deletion (Del-19 as
per Uellner et al. [1997]), which appears to have influenced
PRF folding, traffic, and function. Although the precise mecha-
nisms of PRF toxicity in the ER and the export machinery are
yet to be fully elucidated, our results implicated two key elements
as being critical for this process: membrane binding and oligo-
merization. These same steps are also fundamentally important
for PRF activity in the context of the immunological synapsebetween the effector and target cells (Baran et al., 2009; Vosko-
boinik et al., 2005).
The current study revealed that theC-terminal dodecapeptide,
specifically the last residue (W555), was essential for host cell
survival by providing efficient export of PRF from the ER. Interfer-
encewith the ‘‘tail’’ resulted in delayed export of PRF from the ER
and calcium-dependent toxic activity that eliminated host RBL,
CTL, or NK cells. Toxicity was limited to medium-high GFP-
expressing cells, as indicated by the fact that the host cells
appeared to tolerate low amounts of mutant PRF expression.
This could be compared to the ability of a cell to tolerate some
small amounts of ‘‘sublytic’’ exogenous PRF, as demonstrated
when using purified recombinant PRF in this study and in the
past (Law et al., 2010; Voskoboinik et al., 2005).
The elimination of high GFP (and PRF)-expressing host cells
was not due to a nonspecific toxic effect of PRF overexpression,
becauseWSDA andDel-12 DAPRF remained completely innoc-
uous to various host cells even though they trafficked poorly
from the ER. This effect was not unique to the C-terminal
mutants, as shown by the fact that delayed ER export of WT
PRF (but not the inactive C2 domain mutant DA) was also
detrimental to the cell. We have also investigated a range of non-
exocytosed, FHL-associated PRFmutants, which had no activity
resulting from protein misfolding (Chia et al., 2009; unpublished
observations). Consistent with our observations, the retention of
these inactive mutants in the ER had no effect on host cell
survival.
We also discovered the necessity of glycosylation for rapid
and efficient delivery of PRF from the TGN to secretory granules.
The amino acid sequence alignment of PRFs from vertebrates
indicates that despite an overall sequence divergence (including
a considerable extension and diversion of the C terminus in lower
vertebrates), at least one N-glycosylation moiety at the
C-terminal peptide is invariably conserved. Similar to the trunca-
tion of theC-terminal peptide, we found that abolition of Gly1 and
Gly2 had no effect on PRF activity per se, but influenced traf-
ficking. Indeed, our studies on RBL, CTL, and NK cells have
confirmed the necessity for at least one (either Gly1 or Gly2 or
a Gain Gly mutant) glycosylation site for efficient PRF export
from the Golgi. Our results indicated that PRF can also travel
to secretory granules through a glycosylation-independent
pathway, but this had less than a 20% contribution to the overall
PRF-dependent cytotoxity of CLs. These data provide at least
a partial explanation for a non-FHL phenotype in I-cell disease
patients, who despite the lack of MPR trafficking still maintain
some cytotoxic lymphocyte activity (Griffiths and Isaaz, 1993).
Why is it important for CLs to utilize a generic trafficking
pathway? First of all, it allows the preservation of biosynthetic
resources, which is favorable for a cell that undergoes massive
transcriptional upregulation upon transition from a naive to an
activated state when PRF becomes expressed. Second, the
reliance on specialized and multicomponent trafficking
machinery would provide an easy escape mechanism for patho-
genic and/or oncogenic viruses. Third, recent studies on PRF
gene structure reveal that it is only the chromatin structure of
a complex regulatory domain that prevents PRF expression
(Pipkin et al., 2007). This creates a potentially volatile environ-
ment, because under certain epigenetic conditions PRF can be
potentially expressed in other cell types. Indeed, recent studiesImmunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc. 887
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Figure 5. The Complete Loss of PRF Glycosylation Causes Impaired Lytic Function and Markedly Reduces Export of PRF from the TGN
(A) 51Cr release assay with flow cytometry-sorted, transiently transfected RBL cells expressing WT, Gly1, and Gly1+Gly2 PRF or the negative control, and Jurkat
T cell targets at the effector/target (E/T) ratios indicated. The values plotted represent relative percent 51Cr release and the data shown are mean ± SE of three
independent experiments for eachmutant and of four independent experiments for WT PRF and the vector-only control. All values have been normalized against
WT PRF at 30:1 E/T ratio (100%); average maximal lysis was 20.4% ± 3.5%. Immunoblot shows the relative PRF expression and glycosylation in each of the RBL
cell populations. EndoH and PNGaseF treatments (+) and buffer-only controls (-) were used to distinguish high mannose from complex glycosylation, respec-
tively, as indicators of PRF export from the ER and the TGN.
(B) 51Cr release assay with flow cytometry-sorted, transiently transfected primary CTL cells from Prf1/mice expressing WT, Gly1, Gly2, and Gly1+Gly2 PRF or
the negative control, and SIINFEKL-pulsed EL-4 target cells at the effector/target (E/T) ratios indicated. The values plotted represent relative percent 51Cr release
normalized against WT PRF at 10:1 E/T ratio (Figure 2C). WT PRF (n = 11), the negative control (n = 11), and Gly2 (n = 3) are from Figure 2C. Gly1 and Gly1+Gly2
data shown are mean ± SE of three independent experiments for each mutant.
(C) 51Cr release assay with flow cytometry-sorted, virally transduced PRF-silenced KHYG1 cells (shPRF) expressing WT, Gly1+Gly2 PRF, or the vector-alone
control, and K562 target cells at the effector/target (E/T) ratios indicated. The values plotted represent relative percent 51Cr release normalized against WT PRF at
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Figure 6. Gain of GlycosylationMutation Restores Cytotoxic Activity
of Gly1+Gly2 PRF
51Cr release assay with flow cytometry-sorted, transiently transfected primary
CTL cells from Prf1/ mice expressing WT, Gly1+Gly2, and Gain Gly PRF or
the negative control and SIINFEKL-pulsed EL-4 target cells at the effector/
target (E/T) ratios indicated. The values plotted represent relative percent 51Cr
release normalized against WT PRF at 10:1 E/T ratio (Figure 2C). WT PRF
(n = 11), the negative control (n = 11) are from Figure 2C andGly1+Gly2 (n = 3) is
from Figure 5B. Gain Gly data shown are mean ± SE of three independent
experiments. Immunoblot shows the relative amounts of PRF expression in
each of the RBL cell populations. EndoH and PNGase F treatments (+) and
buffer-only controls (-) were used to distinguish high mannose from complex
glycosylation as indicators of PRF export from the ER and the TGN.
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Mechanisms of Perforin Traffickinghave demonstrated PRF expression in UV-exposed fibroblasts
that does not cause any toxic response in the host cell (Hernan-
dez-Pigeon et al., 2006, 2007).
Our study sheds new light on how CLs survive under the
burden of PRF expression. We have investigated PRF trafficking
and come to the following conclusions: (1) loss of the C terminus
and the attached glycan does not appear to be required for the
intrinsic activity of PRF; (2) efficient PRF export from the ER to
the Golgi is regulated by the extreme C-terminal peptide, specif-
ically the last amino acid, and is essential for host cell survival; (3)10:1 E/T ratio (Figure 2D). WT PRF (n = 7), the negative control (n = 7), and Gly
independent experiments.
(D–F) Confocal microscopy of RBL cells transiently transfected with WT, Gly1+G
Procedures. After electroporation, the cells were incubated either at 37C (24
subsequently warmed to 37C for the times indicated. Scale bars represent 10 m
(G) Graphical representation of the percentage of WT and Gly1+Gly2, Gain Gly,
alization withMetamorph Analysis Software. WT, Gly1, Gly2, and Gain Gly PRFwe
mean ± SE (n = 4–15 cells) for each time point and statistics were obtained with
analysis.glycosylation does not appear to protect the cell at the level of
the ER; and (4) PRF trafficking from the Golgi to the secretory
granules and/or lysosomes is dependent on N-linked glycans,
potentially through the MPR pathway. Future studies will be
aimed at identifying intercompartmental carriers for PRF, partic-
ularly between the ER and the Golgi. Having developed a range
of mutants and cell lines, we are now in a position to utilize pro-
teomic and genetic approaches to unravel the complex and
intriguing mechanism of PRF regulation.
EXPERIMENTAL PROCEDURES
Cell Culture
Rat Basophil Leukemia cells RBL-2H3 (RBL), Jurkat human T leukemia target
cells (Voskoboinik et al., 2004), primary CTLs of Prf/ C57BL/6 mice that also
express a transgenic T cell receptor (OT-I), EL-4 thymoma target cells (H-2Kb)
(Voskoboinik et al., 2007), KHYG1 human NK cells (Yagita et al., 2000), K562
human erythromyeloblastoid leukemia target cells (Suck et al., 2005), and
primary human NK cells (Bird et al., 1998) were generated and/or maintained
as previously described. All animal studies were performed according to the
ethical guidelines approved by the Peter MacCallum Cancer Centre.
Antibodies
The antibodies used for confocal microscopy were mouse monoclonal anti-
human PRF (dG9) IgG2b (BD PharMingen), mouse monoclonal anti-PDI IgG1
(ERmarker, BD Biosciences), mousemonoclonal anti-LAMP1 IgG1 (lysosomal
and granule marker, Calbiochem), mouse monoclonal anti-EEA1 IgG1 (early
endosomal marker, BD Biosciences), mouse monoclonal anti-MPR IgG2a
(late endosomal marker Novus Biologicals), and rabbit polyclonal anti-
TGN38 (TGN network marker, BD Biosciences). Isotype-specific secondary
antibodies were DyLight 549-conjugated AffiniPure Goat Anti-Mouse IgG2b-
specific antibody (Jackson ImmunoResearch), DyLight 488-conjugated Affini-
Pure Goat Anti-Mouse IgG1-specific antibody (Jackson ImmunoResearch),
and Alexa Fluor 647-conjugated Goat Anti-Mouse IgG2a-specific antibody.
Alexa 647-conjugated Goat anti-rabbit antibody (AlexaFluor) was used to
detect polyclonal primary antibodies. All secondary antibodies were excited
at 488, 549, and 647 nm.
Transient Transfection of Cell Lines and Primary Mouse CTLs
and Cytotoxicity Assays
Point mutations in PRF cDNA (Table 1) were generated with the QuickChange
site-directed mutagenesis system (Stratagene) according to manufacturers’
instructions and fully sequenced. cDNAs encoding human or mouse WT and
mutant PRF were cloned into the pIRES2-EGFP expression plasmid (BD
Biosciences Clontech). All experiments were conducted with human PRF,
unless otherwise indicated in figure legends. The resultant expression plas-
mids were transiently transfected into RBL cells, and the transfectants were
subsequently sorted for cytotoxicity assays as previously described (Vosko-
boinik et al., 2004, 2005). Primary CTLs from Prf/ C57BL/6 OT-I transgenic
mice were transiently transfected with the Amaxa Mouse T Cell Nucleofactor
Kit (Lonza) as previously described (Voskoboinik et al., 2007). RBL cells and
primary CTLs were subsequently sorted by flow cytometry according to their
GFP fluorescence 24 hr after transfection (Voskoboinik et al., 2004). Flow
cytometry data were analyzed with FlowJo (v8.8.6).
Transfected RBL cells and primary CTLs sorted for identical mean GFP fluo-
rescence were used in 51Cr release assays with Jurkat T cells or SIINFEKL2 (n = 3) are from Figure 2D. Gly1+Gly2 data shown are mean ± SE of three
ly2, or Gain Gly PRF. The TGN and PRF were detected as per Experimental
hr) or at 19C for 12 hr (time 0) to inhibit protein traffic from the TGN, and
m.
Gly1, and Gly2 PRF exported from the TGN, as determined by percent coloc-
re exported from the TGN at a faster rate than Gly1+Gly2; *p < 0.05. Results are
a one-way ANOVA with Newman-Keuls Multiple Comparison Test post-hoc
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Table 1. Annotations of Mutant PRF Constructs
Annotation Construct
DA D484A
Gly1 S207D
Gly2 N549Q
Gly2 DA N549Q and D484A
Gly1+Gly2 S207D and N549Q
Del-12 truncated C terminus:
G(D/E)PPGNRSGAVWstop
Del-12 DA truncated C terminus and D484A
WS W555S
Gly1 WS S207D and W555S
WS DA W555S and D484A
Gain Gly S207D, D376N, N549Q
Del-19 truncated C terminus:
YVPQMLLG(D/E)PPGNRSGAVWstop
Point mutations in PRF cDNA were cloned into expression plasmids and
transiently transfected or virally transduced into various cell lines as
described in the Experimental Procedures.
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2007). Golgi-plug containing BFA (1 mg/mL; BD Biosciences) was used to
prevent ER export (Klausner et al., 1992) of transiently transfected PRF in
RBL cells at 37C after prior incubation at 15C, which inhibits trafficking
from the ER to the Golgi compartment (Saraste and Kuismanen, 1984). Cyclo-
hexamide (2 mM) was used to prevent de novo PRF synthesis (Voskoboinik
et al., 2007) after incubation at 37C after prior incubation at 15C in pulse
chase experiments. Transiently transfected RBLs were also used for immuno-
fluorescence microscopy (see below).
Stable Transduction of KHYG1 Cells and Cytotoxicity Assays
For KHYG1 studies, PRF-silenced cell lines were created by overexpressing
miR30-based shRNAs targeting the 30 UTR of PRF1. The sequence of the
21-mer constructs cloned into the retroviral pLMP-cherry vector were
AUCCCGAUUCACCCUGUCCAA and UCGGCUAUCGUUAGUGCUAGU.
HEK293T cells were used to package the amphotropic retrovirus and the viral
supernatant collected to transduce KHYG1 cells. Cherry red-positive cells
were sorted by flow cytometry for selection of KHYG1 shPRF cells. For
KHYG1 complementation assays, the coding sequence of human WT PRF
and variants was cloned into the retroviral MSCV-GFP vector. HEK293T cells
were used to package the amphotropic retrovirus and the viral supernatant
collected to transduce KHYG1 shPRF cells. GFP-positive cells were sorted
by flow cytometry for selection of PRF-expressing KHYG1 shPRF cells. Trans-
duced KHYG1 cells were subsequently sorted by flow cytometry according to
their cherry and GFP fluorescence and used in 51Cr release assays with K562
cells as targets.
Expression of Recombinant PRF
The recombinant PRF was expressed and purified with a baculovirus expres-
sion system as described previously (Voskoboinik et al., 2004). Purified WT
PRF and z-PRF were also digested to completion with trypsin and the resul-
tant peptides were analyzed by mass spectrometry (API 4000, Applied
Biosystems) to verify the C-terminal sequence of the protein (data not shown).
Activity of purified recombinant PRF was assessed with sheep red blood cell
lysis, 51Cr release, and apoptosis assays, as described earlier (Sutton et al.,
2008).
Metabolic Labeling and Pulse-Chase
RBL cells were transiently transfected with WT or WS PRF and grown over-
night as described previously (Voskoboinik et al., 2004). The cells were then
‘‘starved’’ in (Met+Cys)-free DMEM supplemented with dialyzed 10% fetal
calf serum for 1 hr and subsequently labeled with 200 mCi 35S-(Met+Cys) for890 Immunity 34, 879–892, June 24, 2011 ª2011 Elsevier Inc.40 min. The cells were washed twice with complete DMEM, and then grown
in a complete DMEM media for 0, 30, 120, and 240 min. The cells were then
lysed (0.1% NP-40, 250 mM NaCl, 1 mM EDTA [pH 7.4]), and PRF was immu-
noprecipitated with anti-human PRF antibody (dG9) and protein G beads for
3 hr at 4C. The beads were washed with lysis buffer three times and once
with the same buffer supplemented with 500 mM NaCl. PRF was eluted with
100 mM glycine (pH 2.5) and neutralized with Tris (pH 9.0), and aliquots
were treatedwith EndoH or PNGaseF according to themanufacturer’s instruc-
tions (New England Bio-Labs). After digestion, untreated control and digested
samples were run on a 9% acrylamide Tris-glycine gel, dried, and analyzed
with a phosphorimager (GE Healthcare). The samples were quantified with
Image Quant TL (GE Healthcare) software.
Electrophoresis and Immunoblotting
Purified recombinant PRF and cell lysates from transiently transfected RBL,
primary CTLs from Prf1/ OT-I transgenic mice, and stably transduced
PRF-silenced KHYG1 cells were resolved on 9% SDS-PAGE (Tris-Glycine)
gels, which were then analyzed for PRF expression by immunoblotting with
rat anti-human PRF mAb P1-8 (Kawasaki et al., 1990), followed by secondary
HRP-linked anti-rat Ig (Dako) (Voskoboinik et al., 2004). Actin (as detected by
mouse anti-human actin mAb, Sigma) was used as a loading control. The
signal was amplified by chemiluminescence and detected on X-ray film (Amer-
sham-Pharmacia). EndoH and PNGaseF glycosidase treatment was conduct-
ed according to the manufacturer’s instructions (New England Biolabs).
Intracellular Flow Cytometry Analysis
Primary human NK cells, RBL cells transiently transfected with human WT
PRF, KHYG1 cells, and KHYG1 PRF-silenced cells were processed as follows.
Cells were washed twice with flow cytometry buffer (13 PBS+1% FCS), then
fixed with BD cytofix/cytoperm (BD Biosciences) for 20 min on ice. Cells were
washed twice with 13 BD cytoperm/cytowash (BD Biosciences) and incu-
bated on ice with mouse Monoclonal Anti-human perforin biotin conjugated
(dG9) (Ancell Corporation) for 30 min. After two washes with 13 BD cyto-
perm/cytowash, cells were incubated with PE-Cy5.5 conjugated Strepdavidin
(eBioscience) for 30 min on ice. Cells were then washed twice with 13 BD
cytoperm/cytowash and analyzed for PRF expression by flow cytometry
with FlowJo (v8.8.6).
Immunofluorescence Microscopy
RBL cells were transiently transfected with human WT or mutant PRF cDNA
and plated into 8-well chamber slides to adhere overnight. Cells were rinsed
with PBS, then fixed in cold methanol (20C) for 2 min on ice. After three
rinses in PBS, cells were blocked in PBS containing 1% BSA for 2 hr at
room temperature. The cells were subsequently incubated with appropriate
antibodies for 2 hr at room temperature, rinsed three times in PBS for
10 min, and stained with secondary antibodies for 1 hr at room temperature.
Cells were rinsed three times in PBS for 10 min and sealed with a coverslip
with antifade mounting reagent (Molecular Probes). The cells were imaged
with an Olympus FV1000 Confocal Microscope equipped with a 12.9 mW
488 nm multi-ion Argon laser, a 1 mW 543 nm green HeNe laser, and a 11
mW 633 nm red He Ne laser. All images were captured with a PlanApoN X
60 oil immersion objective (NA = 1.42). The images were subsequently pro-
cessed with the Olympus Micro FV10-ASW program and analyzed with Meta-
morph software (v7.7 Universal Imaging Corp.) to determine the percentage
colocalization or the correlation coefficient between proteins from single-plane
images. Background was corrected where necessary with non-GFP-express-
ing cells to remove autofluorescence and achieve a background of 0 pixel
intensity. Final images are displayed as z-stack projections and orthogonal
projections were obtained with the Olympus Micro FV10-ASW program
(sections = 0.42 mm).
Time-Lapse Microscopy
RBL cells were transiently transfected with human WT or mutant PRF cDNA
and plated in 12-well culture plates at 37C in a humidified CO2 incubator
for 1 hr. The plates were transferred to a motorized XY stage (Prior Proscan;
GT Vision) on an Olympus IX-81 microscope, which was maintained at 37C
with a Solent (UK) environmental chamber. PI was added to the cultures at
50 ng/ml. Cells were viewed with a 203 LCPlanFL NA 0.40 lens (Olympus)
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Mechanisms of Perforin Traffickingfor the times indicated. Images were captured at specified intervals with an
Orca-ER CCD camera (Hamamatsu) controlled by MetaMorph software
(v7.7 Universal Imaging Corp.).
Statistical Analysis
Paired t test (when comparing two groups of samples) and a one-way ANOVA
with a Newman-Keuls Multiple Comparison Test post-hoc analysis (when
comparing more than two groups of samples) were used for statistical anal-
yses. The application of one or another test is indicated in figure legends.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two movies and can be
found with this article online at doi:10.1016/j.immuni.2011.04.007.
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